Autism Spectrum Disorder (ASD)Phase 2NCT06757504
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
A Phase 2 study testing TTYP01 Tablets (12mg or 18mg) in people with Autism Spectrum Disorder (ASD), run by Shanghai Auzone Biological Technology Co., Ltd. at 5 sites in China.
Trial summary
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD. Read more about this study
- Who is it for?
- Ages 6 to 16 years
- Conditions the study is for
- Autism Spectrum Disorder (ASD)
- What is being tested?
- TTYP01 Tablets (12mg or 18mg)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 5 sitesChina
- Study dates
- 13 Jan 2025to 8 May 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Participants are eligible for the study only if all of the following inclusion criteria are met:
- Aged ≥ 6 to <16 years at the time of signing the ICF (age <16 years after 12-week treatment), including adolescents aged ≥ 12 to<16 years at the time of signing the ICF (age <16 years after 12-week treatment), and children aged ≥ 6 to<12 years at the time of signing the ICF;
- Male or female;
- Participants diagnosed with ASD according to the ASD diagnostic criteria in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and confirmed by the Schedule for Affective Disorders and Schizophrenia for School Aged Children Present and Lifetime version (K-SADS-PL), DSM-5 ASD module;
- Child Autism Rating Scale 2-ST (CARS 2-ST) raw score ≥36;
- CGI-S score ≥4;
- Participants and their legal guardians understand and are willing to participate in this trial, with ICF signed by the legal guardian and participants aged ≥ 8 years; for participants who, at the discretion of the investigator, have cognitive deficits that prevent them from signing the ICF, their legal guardians sign the ICF on behalf of them;
- Females of childbearing potential (as defined in Appendix 15.1) agree to remain abstinent or use a reliable method of contraception for the duration of the trial and until 3 months after the last dose of the investigational product.
Who cannot join
- Any participant who meets any of the following criteria will be excluded:
- Weight <20.0 kg or >70.0 kg, or BMI ≥35.0 kg/m^2;
- Pregnant or lactating women;
- Presence of a serious mental disorder as assessed by the investigator, e.g., schizophrenia, bipolar disorder, depressive disorder, etc.; the presence of significant anxiety, tension, agitation, fear, depression, or the presence of suicidal risk, significant risk of self-injury, impulsivity, aggression, or behaviors based on the medical history and the routine mental status examination;
- History of epileptic seizures within 3 months prior to screening, or presence of a history of severe physical or neurological disease, history of severe head trauma;
- Participants with a history or symptoms of other mental illness that, at the discretion of the investigator, may affect the results of the study;
Show all 17Show fewer
- Participants with a history of any unstable physical or neurological condition or currently suffering from a physical or neurological condition that, at the discretion of the investigator, may put them at risk of a significant adverse event or interfere with the assessment of safety and efficacy during the course of the trial;
- Pre-existing educational training and/or behavioral treatments fail to be stabilized prior to screening and consistent throughout the trial;
- Participants who are unable to discontinue or may use other treatments during the screening period and throughout the trial due to their condition, including: antipsychotic medications (except those that may be used in combination during the trial as specified in the protocol), medications that may have a therapeutic effect on ASD, nootropic drugs, medications for ADHD, intestinal flora modification, and other intestinal flora modification supplementation alternatives;
- Participants who have used treatment modalities such as transcranial magnetic stimulation therapy, direct current stimulation therapy, electroencephalographic biofeedback therapy, auditory integration training, executive function training, acupuncture therapy, etc., within 2 months prior to randomization, or may use such treatments during the treatment period;
- 12-ECG and laboratory results as outlined below: (1)QTc is outside the normal range of the site; (2)Platelets are below the lower limit of normal for the site; (3)Haemoglobin is below the lower limit of normal for the site; (4)Neutrophil count is below the lower limit of normal for the site; (5)ALT or AST ≥ 2 × upper limit of normal, or total bilirubin > upper limit of normal for the site; (6)Urea nitrogen or creatinine is above the upper limit of normal for the site; (7)Any other abnormal laboratory, vital sign, or 12-ECG findings that, at the discretion of the investigator, are abnormal and clinically significant and will affect the safety of the participant or the interpretation of the study results;
- Participation in any clinical trial of a drug or non-drug intervention within the last 1 month;
- Concomitant medications/therapies that are prohibited in the protocol may be required during the trial;
- Participants expected to undergo elective surgery during the trial;
- Participants whose parents/guardians are unable to understand and/or complete the scale assessments in this trial.
- Hypersensitivity to edaravone and excipients (Soluplus, sodium bisulphite, microcrystalline cellulose, magnesium stearate, polyvinylpolypyrrolidone) in TTYP01 tablets;
- Participants who are judged by the investigator to be ineligible for other reasons.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
China5 sites, 5 recruiting
- Recruiting
Peking University Sixth Hospital
Beijing
Jing Liu
- Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha
Xuerong Luo
- Not yet recruiting
West China Hospital of Sichuan University
Chengdu
Yi Huang
- Not yet recruiting
Nanjing Brain Hospital, The Affiliated Brain Hospital of Nanjing Medical University
Nanjing
Xiaoyan Ke
- Not yet recruiting
Tianjin Mental Health Center
Tianjin
Ling Sun
About this study
Official title: A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
Read the detailed description
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
The trial will be conducted in 3 stages. It plans to firstly enroll 24 adolescent participants (≥12 to < 16 years) with ASD. After all the 24 adolescent participants have completed the 4-week follow-up and observation, the Data and Safety Monitoring Board (DSMB) will review the data obtained from these adolescent participants, and then make a recommendation on whether to enroll pediatric participants (≥6 to < 12 years) with ASD and continue the adolescent participants' enrollment, whether it is necessary to adjust the protocol, or whether to terminate the trial for safety considerations, etc. If pediatric participants can be enrolled, it plans to first enroll 24 pediatric participants, and the DSMB will review all data after all these participants have completed the 4-week follow-up and observation, and then make a recommendation on whether to continue enrollment of adolescent and pediatric participants, whether to adjust the protocol, or whether to terminate the trial for safety considerations, etc. If the enrollment of adolescent and pediatric participants can be continued, the trial will proceed to Stage 3 until 150 adolescent and pediatric participants with ASD are enrolled. In addition, throughout the trial, the DSMB may conduct irregular reviews of safety, tolerability, PK, and efficacy data, and give recommendations based on the results of the review, including but not limited to adjusting the trial protocol and early termination of the trial for safety considerations. A DSMB review is triggered if a neurotoxicity AE occurs. The composition, responsibilities, etc. of the DSMB are described in Section 4.2 of the protocol.
Eligible participants will be randomized in a 1:1:1 ratio to receive TTYP01 low-dose, TTYP01 high-dose and placebo treatment. Randomization is stratified by age group (≥12 vs < 12 years of age). Participants will be given the corresponding dose of the investigational product for 12 weeks based on their weight and groups as listed in the table in the protocol. The dosing regimen can be adjusted based on the safety, tolerability, PK and other data accumulated in the previous period.
- Conditions
- Autism Spectrum Disorder (ASD)
- Being tested
- TTYP01 Tablets (12mg or 18mg), Placebo (Simulant TTYP01 Tablets)
- Medical subject headings
- Autism Spectrum Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TTYP01 Tablets (12mg or 18mg)Drug
Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Placebo (Simulant TTYP01 Tablets)Drug
Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
| Study group | Role | What they receive |
|---|---|---|
| TTYP01 low-dose group | Experimental | TTYP01 Tablets (12mg or 18mg), Twice daily for 12 weeks. Dosage is determined based on body weight and group assignment, with the low-dose group receiving 12mg-30mg BID, the dosing regimen is detailed in the trial protocol. Receives: Drug: TTYP01 Tablets (12mg or 18mg); Drug: Placebo (Simulant TTYP01 Tablets) |
| TTYP01 high-dose group | Experimental | TTYP01 Tablets (12mg or 18mg), Twice daily for 12 weeks. Dosage is determined based on body weight and group assignment, with the high-dose group receiving 24mg-60mg BID, the dosing regimen is detailed in the trial protocol. Receives: Drug: TTYP01 Tablets (12mg or 18mg); Drug: Placebo (Simulant TTYP01 Tablets) |
| Placebo group | Placebo comparator | Simulant TTYP01 Tablets, Twice daily for 12 weeks. Receives: Drug: Placebo (Simulant TTYP01 Tablets) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal） scores at Week 12.
The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal）, ABC-I, A, C （Aberrant Behavioral Checklist - Irritability, Agitation, Crying）, ABC-SB （Aberrant Behavioral Checklist - Stereotypic Behavior）, ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed.
The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.
Measured: At baseline and week 12
Incidence and severity of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and TEAEs that lead to treatment discontinuation.
To evaluate the safety and tolerability of TTYP01 tablets in adolescent and pediatric participants with ASD.
Measured: Throughout the trial period
Plasma concentrations and population PK profiles of edaravone and its metabolites in adolescent and pediatric ASD participants.
Concentrations of edaravone and its metabolites are assayed in the plasma of adolescent and pediatric participants with ASD. They will be analyzed with descriptive statistics according to planned sampling points.
Measured: Visit 2 (Day 1): 30 minutes (±5 minutes) and 3 hours (±10 minutes) after the first dose; Visit 8 (Week 12 ±2 Days)or Early withdrawal: before the first dose (0 hour), and 30 minutes (±5 minutes) after the first dose on the day of the visit.
Secondary outcomes (10)
Changes from baseline in ABC-SW scores at Weeks 4 and 8.
The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal）, ABC-I, A, C （Aberrant Behavioral Checklist - Irritability, Agitation, Crying）, ABC-SB （Aberrant Behavioral Checklist - Stereotypic Behavior）, ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed.
The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.
Measured: At baseline, Weeks 4 and 8
Changes from baseline in other ABC subscale scores at Weeks 4, 8 and 12.
The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal）, ABC-I, A, C （Aberrant Behavioral Checklist - Irritability, Agitation, Crying）, ABC-SB （Aberrant Behavioral Checklist - Stereotypic Behavior）, ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed.
The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.
Measured: At baseline, Weeks 4, 8 and 12
Clinical Global Impressions-Improvement (CGI-I) scores at Weeks 4, 8, and 12.
The CGI includes the CGI-S and CGI-I. The CGI rating scale allows for an overall assessment of participant improvement over time. At baseline, the CGI-S assessment is performed and the rating investigator rates the severity of the participant's condition based on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). At the follow-up visit, the scoring investigator assessed the degree of improvement in the participant's symptoms relative to baseline based on the CGI-I items on a 7-point scale ranging from 1 (very marked improvement) to 7 (very marked deterioration).
Measured: At Weeks 4, 8, and 12.
Changes from baseline in Clinical Global Impressions-Severity (CGI-S) scores at Weeks 4, 8, and 12.
The CGI includes the CGI-S and CGI-I. The CGI rating scale allows for an overall assessment of participant improvement over time. At baseline, the CGI-S assessment is performed and the rating investigator rates the severity of the participant's condition based on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). At the follow-up visit, the scoring investigator assessed the degree of improvement in the participant's symptoms relative to baseline based on the CGI-I items on a 7-point scale ranging from 1 (very marked improvement) to 7 (very marked deterioration).
Measured: At baseline, Weeks 4, 8 and 12
Changes from baseline in Social Responsiveness Scale 2 (SRS-2) total scores at Weeks 4, 8, and 12.
The SRS-2 assesses participants' social communication, social awareness, social motivation, and self-regulation. Scales can be completed by parents and teachers.Both the SRS-2 total score and the five subscale scores can be used to assess the severity of ASD symptoms. The SRS-2-School Age was used in this study.
The SRS-2 contains 65 items, each of which is rated by the assessor on a scale of 1 (not true), 2 (sometimes true), 3 (often true), and 4 (almost always true) based on the behavioral performance of the person being assessed. Scores range from 65-260, where higher scores indicate more severe social problems.
Measured: At baseline, Weeks 4, 8 and 12
Changes from baseline in Autism Treatment Evaluation Checklist (ATEC) total scores at Weeks 4, 8, and 12.
The ATEC contains four subscales: language/communication, social, sensory/cognitive awareness, and health/physical/behavioral, and scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others who know the person being assessed.
Scores from each subscale are combined to calculate a total score, which ranges from 0 to 179. Higher scores indicate more severe autism symptoms and behavioral problems, and lower scores indicate improvement in symptoms.
Measured: At baseline, Weeks 4, 8 and 12
Changes from baseline in the total score of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV - Home version (ADHD-RS-IV [Home version]) at Weeks 4, 8, and 12.
The ADHD-RS assesses the child's attention deficit and hyperactive/impulsive behaviors over the past six months. Scale ratings can be completed by parents and teachers.
The ADHD-RS consists of 18 items that cover various aspects of attention and hyperactivity symptoms. Participants assess the extent of each item based on their performance using a four-point scale:0 (Never or Rarely), 1 (Sometimes), 2 (Often), and 3 (Very Often). By combining these items, a composite score can be derived that measures the severity of attention deficit and hyperactivity symptoms. Higher scores indicate more severe symptoms.
Measured: At baseline, Weeks 4, 8 and 12
Changes from baseline in Behavior Rating Inventory of Executive Function (BRIEF) (Parent Version) scores at Weeks 4, 8, and 12.
The Children's BRIEF (Parent Version) assesses executive functioning in children and adolescents, including aspects of working memory, planning/organization, and task monitoring, and the scale can be completed by a parent or guardian. The first version of the Children's BRIEF (Parent Version) was used in this study.
The parent version of the BRIEF for school-age children assesses the executive functioning of children aged 6 to 18 years old, and contains 86 items divided into 2 latitudes: behavioral regulation index (BRI, including 3 factors of inhibition, switching and emotional control) and metacognition index (MI, including 5 factors of task initiation, working memory, planning, organizing and monitoring). Each item was rated on a scale of 1 to 3 (1=never; 2=sometimes; 3=often), with higher ratings reflecting more severe impairment of executive function.
Measured: At baseline, Weeks 4, 8 and 12
Proportion of participants with ≥25% reduction in ABC-SW score relative to baseline at Week 12.
The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal）, ABC-I, A, C （Aberrant Behavioral Checklist - Irritability, Agitation, Crying）, ABC-SB （Aberrant Behavioral Checklist - Stereotypic Behavior）, ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed.
The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.
Measured: At baseline and week 12
Proportion of participants with a CGI-I score ≤ 2 at Week 12.
The CGI includes the CGI-S and CGI-I. The CGI rating scale allows for an overall assessment of participant improvement over time. At baseline, the CGI-S assessment is performed and the rating investigator rates the severity of the participant's condition based on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). At the follow-up visit, the scoring investigator assessed the degree of improvement in the participant's symptoms relative to baseline based on the CGI-I items on a 7-point scale ranging from 1 (very marked improvement) to 7 (very marked deterioration).
Measured: At Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2025
- Study start13 Jan 2025
- Primary completion6 Feb 2026 (estimated)
- Study completion8 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum Disorder (ASD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jing Liu, Study chair, Peking University Sixth Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06757504
- Sponsor's protocol ID
- TTYP01-Ⅱ-ASD
- Status last verified
- May 2025
- First submitted
- 25 Dec 2024
- Last updated
- 14 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders
- ClinicalTrials.gov ID
- NCT06757504
- Acronym / sponsor ID
- TTYP01-Ⅱ-ASD
- Conditions
- Autism Spectrum Disorder (ASD)
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 13 Jan 2025 (actual)
- Primary completion
- 6 Feb 2026 (estimated)
- Study completion
- 8 May 2026 (estimated)
- First posted
- 3 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
Detailed description
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
The trial will be conducted in 3 stages. It plans to firstly enroll 24 adolescent participants (≥12 to < 16 years) with ASD. After all the 24 adolescent participants have completed the 4-week follow-up and observation, the Data and Safety Monitoring Board (DSMB) will review the data obtained from these adolescent participants, and then make a recommendation on whether to enroll pediatric participants (≥6 to < 12 years) with ASD and continue the adolescent participants' enrollment, whether it is necessary to adjust the protocol, or whether to terminate the trial for safety considerations, etc. If pediatric participants can be enrolled, it plans to first enroll 24 pediatric participants, and the DSMB will review all data after all these participants have completed the 4-week follow-up and observation, and then make a recommendation on whether to continue enrollment of adolescent and pediatric participants, whether to adjust the protocol, or whether to terminate the trial for safety considerations, etc. If the enrollment of adolescent and pediatric participants can be continued, the trial will proceed to Stage 3 until 150 adolescent and pediatric participants with ASD are enrolled. In addition, throughout the trial, the DSMB may conduct irregular reviews of safety, tolerability, PK, and efficacy data, and give recommendations based on the results of the review, including but not limited to adjusting the trial protocol and early termination of the trial for safety considerations. A DSMB review is triggered if a neurotoxicity AE occurs. The composition, responsibilities, etc. of the DSMB are described in Section 4.2 of the protocol.
Eligible participants will be randomized in a 1:1:1 ratio to receive TTYP01 low-dose, TTYP01 high-dose and placebo treatment. Randomization is stratified by age group (≥12 vs < 12 years of age). Participants will be given the corresponding dose of the investigational product for 12 weeks based on their weight and groups as listed in the table in the protocol. The dosing regimen can be adjusted based on the safety, tolerability, PK and other data accumulated in the previous period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| TTYP01 low-dose group | Experimental | Drug: TTYP01 Tablets (12mg or 18mg), Drug: Placebo (Simulant TTYP01 Tablets)TTYP01 Tablets (12mg or 18mg), Twice daily for 12 weeks. Dosage is determined based on body weight and group assignment, with the low-dose group receiving 12mg-30mg BID, the dosing regimen is detailed in the trial protocol. |
| TTYP01 high-dose group | Experimental | Drug: TTYP01 Tablets (12mg or 18mg), Drug: Placebo (Simulant TTYP01 Tablets)TTYP01 Tablets (12mg or 18mg), Twice daily for 12 weeks. Dosage is determined based on body weight and group assignment, with the high-dose group receiving 24mg-60mg BID, the dosing regimen is detailed in the trial protocol. |
| Placebo group | Placebo comparator | Drug: Placebo (Simulant TTYP01 Tablets)Simulant TTYP01 Tablets, Twice daily for 12 weeks. |
Who may qualify
- Ages
- 6 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (8 listed)
- Participants are eligible for the study only if all of the following inclusion criteria are met:
- Aged ≥ 6 to <16 years at the time of signing the ICF (age <16 years after 12-week treatment), including adolescents aged ≥ 12 to<16 years at the time of signing the ICF (age <16 years after 12-week treatment), and children aged ≥ 6 to<12 years at the time of signing the ICF;
- Male or female;
- Participants diagnosed with ASD according to the ASD diagnostic criteria in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and confirmed by the Schedule for Affective Disorders and Schizophrenia for School Aged Children Present and Lifetime version (K-SADS-PL), DSM-5 ASD module;
- Child Autism Rating Scale 2-ST (CARS 2-ST) raw score ≥36;
Key exclusion criteria (17 listed)
- Weight <20.0 kg or >70.0 kg, or BMI ≥35.0 kg/m^2;
- Pregnant or lactating women;
- Presence of a serious mental disorder as assessed by the investigator, e.g., schizophrenia, bipolar disorder, depressive disorder, etc.; the presence of significant anxiety, tension, agitation, fear, depression, or the presence of suicidal risk, significant risk of self-injury, impulsivity, aggression, or behaviors based on the medical history and the routine mental status examination;
- History of epileptic seizures within 3 months prior to screening, or presence of a history of severe physical or neurological disease, history of severe head trauma;
- Participants with a history or symptoms of other mental illness that, at the discretion of the investigator, may affect the results of the study;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TTYP01 Tablets (12mg or 18mg)Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner. | Drug | TTYP01 high-dose group, TTYP01 low-dose group |
| Placebo (Simulant TTYP01 Tablets)Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner. | Drug | Placebo group, TTYP01 high-dose group, TTYP01 low-dose group |
Primary outcome
Change from baseline in ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal） scores at Week 12.
Time frame: At baseline and week 12
The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal）, ABC-I, A, C （Aberrant Behavioral Checklist - Irritability, Agitation, Crying）, ABC-SB （Aberrant Behavioral Checklist - Stereotypic Behavior）, ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed. The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.
Incidence and severity of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and TEAEs that lead to treatment discontinuation.
Time frame: Throughout the trial period
To evaluate the safety and tolerability of TTYP01 tablets in adolescent and pediatric participants with ASD.
Plasma concentrations and population PK profiles of edaravone and its metabolites in adolescent and pediatric ASD participants.
Time frame: Visit 2 (Day 1): 30 minutes (±5 minutes) and 3 hours (±10 minutes) after the first dose; Visit 8 (Week 12 ±2 Days)or Early withdrawal: before the first dose (0 hour), and 30 minutes (±5 minutes) after the first dose on the day of the visit.
Concentrations of edaravone and its metabolites are assayed in the plasma of adolescent and pediatric participants with ASD. They will be analyzed with descriptive statistics according to planned sampling points.
10 secondary outcomes
Changes from baseline in ABC-SW scores at Weeks 4 and 8.
Time frame: At baseline, Weeks 4 and 8
Changes from baseline in other ABC subscale scores at Weeks 4, 8 and 12.
Time frame: At baseline, Weeks 4, 8 and 12
Clinical Global Impressions-Improvement (CGI-I) scores at Weeks 4, 8, and 12.
Time frame: At Weeks 4, 8, and 12.
Changes from baseline in Clinical Global Impressions-Severity (CGI-S) scores at Weeks 4, 8, and 12.
Time frame: At baseline, Weeks 4, 8 and 12
Changes from baseline in Social Responsiveness Scale 2 (SRS-2) total scores at Weeks 4, 8, and 12.
Time frame: At baseline, Weeks 4, 8 and 12
Changes from baseline in Autism Treatment Evaluation Checklist (ATEC) total scores at Weeks 4, 8, and 12.
Time frame: At baseline, Weeks 4, 8 and 12
Changes from baseline in the total score of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV - Home version (ADHD-RS-IV [Home version]) at Weeks 4, 8, and 12.
Time frame: At baseline, Weeks 4, 8 and 12
Changes from baseline in Behavior Rating Inventory of Executive Function (BRIEF) (Parent Version) scores at Weeks 4, 8, and 12.
Time frame: At baseline, Weeks 4, 8 and 12
Proportion of participants with ≥25% reduction in ABC-SW score relative to baseline at Week 12.
Time frame: At baseline and week 12
Proportion of participants with a CGI-I score ≤ 2 at Week 12.
Time frame: At Week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2025.
Related trials for Autism Spectrum Disorder (ASD)
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jing Liu study chair
Peking University Sixth Hospital
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing TTYP01 Tablets (12mg or 18mg) in people with Autism Spectrum Disorder (ASD), run by Shanghai Auzone Biological Technology Co., Ltd. at 5 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaolong Hou (+86-21-65039008, houxl@auzonebio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in ABC-SW（Aberrant Behavioral Checklist - Social Withdrawal） scores at Week 12. (time frame: At baseline and week 12). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2025.